Nicholas J. Talley
Department of Medicine
University of Sydney
Nepean Hospital
Penrith
Australia
Name/email consistency: high
- New and emerging treatments for irritable bowel syndrome and functional dyspepsia. Talley, N.J. Expert. Opin. Emerg. Drugs (2002)
- Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial. Talley, N.J., Verlinden, M., Snape, W., Beker, J.A., Ducrotte, P., Dettmer, A., Brinkhoff, H., Eaker, E., Ohning, G., Miner, P.B., Mathias, J.R., Fumagalli, I., Staessen, D., Mack, R.J. Aliment. Pharmacol. Ther. (2000)
- Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months' follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group. Talley, N.J., Janssens, J., Lauritsen, K., Rácz, I., Bolling-Sternevald, E. BMJ (1999)
- Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. Talley, N.J., Vakil, N., Ballard, E.D., Fennerty, M.B. N. Engl. J. Med. (1999)
